Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683696 · ClinicalTrials.gov registry record · Phase 2
Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)
A Phase 2 study, sponsored by Biotronik.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,680
- Enrollment target
NCT00683696 is a Phase 2 study that was terminated before completion, run by Biotronik. The registered enrollment target is 1,680 participants.
The verdict
NCT00683696, a Phase 2 study, was terminated before completion, sponsored by Biotronik.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,680 participants
- Enrollment target
Study Summary
The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (\< 130 ms) and echocardiographic evidence of ventricular dyssynchrony.
Interventions
- DEVICE Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,680 participants |
| Start Date | 2008-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00683696
The ClinicalTrials.gov registry entry for NCT00683696 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,680 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biotronik, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D) is the first listed.
NCT00683696 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00683696 about?
NCT00683696 is a clinical study titled "Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)". The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (\< 130 ms) and echocardiographic evidence of ...
What is the current status of trial NCT00683696?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,680 participants. The study started on 2008-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00683696?
The interventions under investigation include: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D) (DEVICE).
Who is sponsoring clinical trial NCT00683696?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.